(Breaking) News/Reports/Analysis • DIGITAL ONLY
Founded 1967
Subscription Mailbox Member
Price Drop: 12 months €69
Welcome on Monday to the delayed headline news site Twitts.nl, but subscribe to real-time mailbox trial version RTLIVE-NEWS/PersNieuwsLIVE/NieuwsNowLIVE (€0.19 per day) Contact - info@persnieuws.com
Johnson & Johnson's Phase 3 prostate cancer study shows ERLEADA® (apalutamide) before and after surgery significantly reduces risk of metastasis or death, breaking a decades-long treatment paradigm